Moving from Late-Onset Pompe Disease to Cipaglucosidase Alfa/Miglustat Improves Motor Function and Quality of Life.

CTAD: Clinical Trials on Alzheimer's Disease Conference

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

Decoding Multifocal Motor Neuropathy: A Practical Guide to Diagnosis, Pathogenesis, and Emerging Innovations in Treatment

Decoding Multifocal Motor Neuropathy: A Practical Guide to Diagnosis, Pathogenesis, and Emerging Innovations in Treatment

AAN: American Academy of Neurology

ISC: International Stroke Conference

CTAD Video Pearls: Video Pearls from the Clinical Trials on Alzheimer's Disease Conference

AES: American Epilepsy Society

Rat Lungworm Is Now in My State. Is It in Yours Too?

The global, brain-invading parasite continues to spread

Severe Malaria in Kids Linked to Certain Cognitive, Academic Deficits Years Later

Impairment persisted after episodes of cerebral malaria or severe malarial anemia

Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy

Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study

Suppressing a Sneeze May Have Led to Cerebrospinal Fluid Leak

While normally harmless, holding in a sneeze may in rare cases cause serious problems

First Clinical Trial in MOGAD Meets Primary Endpoint

Satralizumab cuts relapse risk in myelin oligodendrocyte glycoprotein antibody-associated disease

Cemdisiran siRNA Therapy Demonstrates Efficacy in Myasthenia Gravis

Investigational treatment improves outcomes without complete complement blockade

Stiff Person Syndrome Patients Regain Mobility After Single-Dose Cell Therapy

CAR-T therapy shows promise in clinical trial

Cell Therapy Slows Upper Limb Decline in Duchenne Muscular Dystrophy

Investigational deramiocel is back under FDA review again

Real-World Registry Study Shows Alzheimer's Drug Safety Outcomes

No new signals for lecanemab emerged in ALZ-NET